Actively Recruiting
Study on Preliminary Safety and Efficacy of Adaptive DBS Aligned to Locomotor States to Improve Locomotor Functions in Parkinson's Patients
Led by Jocelyne Bloch · Updated on 2025-12-17
10
Participants Needed
1
Research Sites
104 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
At present, there is no cure for Parkinson's disease. The standard treatment involves taking dopaminergic drugs. When drugs lose their effectiveness, they can be supplemented by Deep Brain Stimulation (DBS) therapy. Medication and deep brain stimulation are effective for motor problems such as tremors, slowness of movement, and muscle stiffness. However, there is no effective treatment for walking and balance problems that occur during the course of the disease. DBS neurostimulators not only stimulate, but also record brain activity in the region in which the electrodes are implanted. This brain activity changes over time, depending on the individual's general state (i.e., medication, eating), movements (sitting, standing or walking) and motor problems (i.e., problems of gait initiation and termination, balance problems and freezing of gait). Adaptive deep brain stimulation (aDBS) makes it possible to change the stimulation according to brain activity, and thus to these different states. This method involves using the usual Medtronic Percept neurostimulator with its adaptive therapy active. Additional investigational features for adaptive therapy are available within the study. In this study, we want to evaluate whether adaptive deep brain stimulation is safe and effective in improving walking problems in people with Parkinson's disease.
CONDITIONS
Official Title
Study on Preliminary Safety and Efficacy of Adaptive DBS Aligned to Locomotor States to Improve Locomotor Functions in Parkinson's Patients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosed with typical or atypical forms of Parkinson's disease with gait or balance disorders
- Implanted with a full Medtronic Percept neurostimulator system including specific bilateral leads and extensions
- Show brain activity modulations related to locomotor states or gait deficits
- Aged 18 years or older
- Able to provide and sign informed consent before study procedures
- Able to understand and communicate in French
- Willing to comply with all study recording conditions and attend all required procedures
You will not qualify if you...
- Use of interleaved DBS programs incompatible with adaptive DBS
- Presence of high impedances or artifacts in neural signals blocking detection of motor-related biomarkers
- Poor tolerance to changes in DBS amplitude
- Gait problems from causes other than Parkinson's disease
- Inability to follow study procedures independently
- History of major psychiatric or neurocognitive disorders as judged by investigators
- Planned major changes in Parkinson's treatments during the study
- History of drug or alcohol abuse in the past 5 years
- Pregnancy
- Participation in another investigational study within 30 days before or during this study
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
CHUV
Lausanne, Canton of Vaud, Switzerland, 1011
Actively Recruiting
Research Team
J
Jocelyne Bloch, Prof. MD
CONTACT
E
Eduardo Martin Moraud, Prof.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here